1397TiP Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Liu, S.V., Dziadziuszko, R., Viteri, S., Cappuzzo, F., Comis, S., Gabarre, V., Chevalier, C., Vandewalle, T., Montestruc, F., Vasseur, B., Remon Masip, J., Besse, B.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
P4.11D.12 Phase 3 Trial of OSE2101 Versus Docetaxel in Patients with Non-Small Cell Lung Cancer & Secondary Resistance to Immunotherapy
Liu, S.V., Singh, J., Yang, X., D'olimpio, J., Cappuzzo, F., Dziadziuszko, R., Viteri, S., Chevalier, C., Comis, S., Vandewalle, T., Gabarre, V., Montestruc, F., Vasseur, B., Remon, J., Besse, B.
Published in Journal of thoracic oncology (01.10.2024)
Published in Journal of thoracic oncology (01.10.2024)
Get full text
Journal Article
1592TiPATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Felip, E, Besse, B, Dziadziuszko, R, Cobo Dols, M, Denis, F, García-Campelo, M-R, Debieuvre, D, Catino, A, Moran Bueno, M T, Madroszyk Flandin, A-C, Masson, P, Chouaid, C, Lianes, P, Cappuzzo, F, Delmonte, A, Robinet, G, Romano, G, Gabarre, V, Remon Masip, J, Giaccone, G
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Felip, E., Besse, B., Dziadziuszko, R., Cobo Dols, M., Denis, F., García-Campelo, M.-R., Debieuvre, D., Catino, A., Moran Bueno, M.T., Madroszyk Flandin, A.-C., Masson, P., Chouaid, C., Lianes, P., Cappuzzo, F., Delmonte, A., Robinet, G., Romano, G., Gabarre, V., Remon Masip, J., Giaccone, G.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1592TiP - ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Felip, E., Besse, B., Dziadziuszko, R., Cobo Dols, M., Denis, F., García-Campelo, M.-R., Debieuvre, D., Catino, A., Moran Bueno, M.T., Madroszyk Flandin, A.-C., Masson, P., Chouaid, C., Lianes, P., Cappuzzo, F., Delmonte, A., Robinet, G., Romano, G., Gabarre, V., Remon Masip, J., Giaccone, G.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article